KCM
SCPH

Kingdon Capital Management’s scPharmaceuticals SCPH Stock Holding History

Kingdon Capital Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-659,711
Closed -$2.51M – 96
2025
Q2 		$2.51M Sell
659,711
-340,289
-34% -$1.06M 0.34% 63
2025
Q1 		$2.63M Buy
1,000,000
+200,000
+25% +$651K 0.28% 58
2024
Q4 		$2.83M Hold
800,000
– – 0.4% 60
2024
Q3 		$3.65M Buy
+800,000
New +$3.87M 0.4% 65

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Kingdon Capital Management's SCPH Position: Q3 2025 in Review

Kingdon Capital Management sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 659,711 shares — an estimated $2.51M sold.

Kingdon Capital Management first reported a position in SCPH in Q3 2024 and held it in 4 quarters. The position peaked at $3.65M in Q3 2024. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

  • Kingdon Capital Management reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kingdon Capital Management sold 659,711 scPharmaceuticals shares in Q3 2025, an estimated $2.51M.
  • Kingdon Capital Management first reported a position in scPharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Kingdon Capital Management's scPharmaceuticals position peaked at $3.65M in Q3 2024.
  • 110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on Kingdon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.